reports
iCAD Reports Financial Results for First Quarter Ended March 31, 2025
iCAD Reports Financial Results for First Quarter Ended March 31, 2025 NASHUA, N.H., May 13, 2025 (GLOBE NEWSWIRE) -- iCAD, Inc. (NASDAQ: ICAD) ("iCAD" or the "Company") a global leader on a mission to create a world where cancer can’t hide by providing clinically proven AI-powered breast health solutions, today reported its financial and operating results for the three months ended March 31, 2025. First Quarter 2025 Highlights (Year over Year Performance): Total ARR (Annual Recurring Revenue) was $10.7 million, up 18% year over yearQ1 total revenues of $4.9 millionGross Profit Margin o...
iCAD Collaborates with Microsoft to provide access to its Mammography ...
iCAD Collaborates with Microsoft to provide access to its Mammography Solutions in Microsoft’s Precision Imaging Network (PIN) iCAD collaborates with Microsoft to offer radiology providers the option for automated patient reporting on mammography results through PowerScribe integration NASHUA, N.H., April 29, 2025 (GLOBE NEWSWIRE) -- . (NASDAQ: ICAD) (“iCAD” or the “Company”), a global leader in clinically proven AI-powered cancer detection solutions, announced today a collaboration with Microsoft, to include a set of AI-powered mammography solutions in iCAD’s ProFound Breast Health Sui...
iCAD Expands Executive Leadership with Appointment of Mark Koeniguer a...
iCAD Expands Executive Leadership with Appointment of Mark Koeniguer as Chief Commercial Officer NASHUA, N.H., April 08, 2025 (GLOBE NEWSWIRE) -- iCAD, Inc. (NASDAQ: ICAD) ("iCAD" or the "Company") a global leader on a mission to create a world where cancer can’t hide by providing clinically proven AI-powered breast health solutions, today announced the appointment of Mark Koeniguer as Chief Commercial Officer (CCO), to lead the next phase of global growth for iCAD. As CCO at iCAD, Koeniguer will assume responsibilities for revenue growth across North America and around the globe, bringi...
iCAD Reports Financial Results for Fourth Quarter and Fiscal Year Ende...
iCAD Reports Financial Results for Fourth Quarter and Fiscal Year Ended December 31, 2024 NASHUA, N.H., March 19, 2025 (GLOBE NEWSWIRE) -- iCAD, Inc. (NASDAQ: ICAD) ("iCAD" or the "Company") a global leader on a mission to create a world where cancer can’t hide by providing clinically proven AI-powered breast health solutions, today reported its financial and operating results for the fourth quarter and full year ended December 31, 2024. Fourth Quarter 2024 Highlights (Year-over-Year Performance): Total ARR (Annual Recurring Revenue) was $9.8 million, up 11% year over yearTotal revenue...
iCAD to Report Fourth Quarter and Full Year 2024 Financial Results on ...
iCAD to Report Fourth Quarter and Full Year 2024 Financial Results on March 19, 2025 NASHUA, N.H., March 11, 2025 (GLOBE NEWSWIRE) -- . (NASDAQ: ICAD), a global leader in clinically proven AI-powered cancer detection solutions, announced today it will release financial results for the fourth quarter and year ended December 31, 2024, after market close, and host a conference call at 4:30 PM Eastern Time on Wednesday, March 19, 2025. Earnings call details are as follows: Toll Free: 877-545-0523International: 973-528-0016Participant Access Code: 174549Webcast: About iCAD, Inc. iCAD, Inc....
iCAD and RamSoft Announce Partnership to Deliver ProFound® AI-Powered ...
iCAD and RamSoft Announce Partnership to Deliver ProFound® AI-Powered Mammography Solutions Across North America NASHUA, N.H. and TORONTO, March 05, 2025 (GLOBE NEWSWIRE) -- . (NASDAQ: ICAD) a global leader in clinically proven AI-powered cancer detection solutions, and RamSoft®, a global leader in cloud-based RIS/PACS radiology solutions for imaging centers and providers, today announced a new strategic commercial preferred distributor and integration partnership across the US and Canada. With over 750 sites and thousands of healthcare providers worldwide utilizing RamSoft’s solutions, t...
Koios Medical and iCAD Partner to Expand AI-Powered, Multi-Modality Br...
Koios Medical and iCAD Partner to Expand AI-Powered, Multi-Modality Breast Cancer Detection Solutions at ECR 2025 NASHUA, N.H. and CHICAGO, Feb. 26, 2025 (GLOBE NEWSWIRE) -- . (NASDAQ: ICAD) a global leader in clinically proven AI-powered cancer detection solutions, and , a leader in AI-driven ultrasound cancer diagnosis, today announced a strategic reseller partnership to deliver a comprehensive, multi-modality AI suite for breast cancer detection. This collaboration integrates iCAD’s ProFound AI® Breast Health Suite for mammography with Koios SmartUltrasound™, providing radiologists wit...
iCAD To Showcase Five AI-Powered Research Presentations Advancing Brea...
iCAD To Showcase Five AI-Powered Research Presentations Advancing Breast Cancer Detection, Risk Evaluation, and Breast Arterial Calcification Assessment at ECR 2025 NASHUA, N.H., Feb. 19, 2025 (GLOBE NEWSWIRE) -- iCAD, Inc. (NASDAQ: ICAD) ("iCAD" or the "Company") a global leader on a mission to create a world where cancer can’t hide by providing clinically proven AI-powered breast health solutions, today announced that five clinical presentations and abstracts highlighting the Company’s advancements in breast cancer detection, risk evaluation, and breast arterial calcification (BAC) asse...
iCAD Pre-Announces Estimated Q4 2024 Revenue
iCAD Pre-Announces Estimated Q4 2024 Revenue iCAD to Participate in the BTIG at Snowbird:12th Annual MedTech, Digital Health, Life Science & Diagnostic Tools Conference NASHUA, N.H., Jan. 27, 2025 (GLOBE NEWSWIRE) -- iCAD, Inc. (NASDAQ: ICAD) (“iCAD” or the “Company”), a global leader on a mission to create a world where cancer can’t hide by providing clinically proven AI-powered breast health solutions, today reported select preliminary, unaudited financial results for the fourth quarter of 2024. Based on preliminary, unaudited financial information, the Company expects total revenue ...
SABCS 2024: New Research Assesses iCAD’s Image Based AI-Risk, Detectio...
SABCS 2024: New Research Assesses iCAD’s Image Based AI-Risk, Detection, and Breast Arterial Calcifications (BAC) Assessment Across Diverse Populations Reveals Higher Prevalence of Breast Arterial Calcifications (BAC) in Breast Cancer Patients, Suggesting Potential Need for Cardiovascular Assessment Alongside Oncological Treatment NASHUA, N.H., Dec. 11, 2024 (GLOBE NEWSWIRE) -- . (NASDAQ: ICAD) (“iCAD” or the “Company”) a global leader in clinically proven AI-powered cancer detection solutions, announced today that four novel AI-driven breast cancer research abstracts have been accepted...
CORRECTION – iCAD Advances Fight Against Breast Cancer with FDA-cleare...
CORRECTION – iCAD Advances Fight Against Breast Cancer with FDA-cleared, Next-Generation AI Solutions and ProFound Health Partnership with Cascaid Health at RSNA 2024 ProFound Health, a Virtual Care Partnership with Cascaid Health, to Democratize Access to AI-Powered Mammography for All Patients – Launching Q1 2025 NASHUA, N.H., Dec. 04, 2024 (GLOBE NEWSWIRE) -- Further to a release issued under the same headline on November 26, 2024 13:00 ET by iCAD, Inc., the headline and fourth paragraph have been updated to acknowledge a pending trademark application for the mark “SecondReadAI” by L...
iCAD Advances Fight Against Breast Cancer with FDA-cleared, Next-Gener...
iCAD Advances Fight Against Breast Cancer with FDA-cleared, Next-Generation AI Solutions and a Second-Read AI Partnership with Cascaid Health at RSNA 2024 ProFound Health, a Virtual Care Partnership with Cascaid Health, to Democratize Access to AI-Powered Mammography for All Patients – Launching Q1 2025 NASHUA, N.H., Nov. 26, 2024 (GLOBE NEWSWIRE) -- . (NASDAQ: ICAD) (“iCAD” or the “Company”), a global leader in clinically proven AI-powered cancer detection solutions, will showcase its groundbreaking breast health AI technologies at the Radiological Society of North America (RSNA) 2024 ...
iCAD Reports Financial Results for Third Quarter Ended September 30, 2...
iCAD Reports Financial Results for Third Quarter Ended September 30, 2024 NASHUA, N.H., Nov. 13, 2024 (GLOBE NEWSWIRE) -- iCAD, Inc. (NASDAQ: ICAD) ("iCAD" or the "Company") a global leader on a mission to create a world where cancer can’t hide by providing clinically proven AI-powered breast health solutions, today reported its financial and operating results for the three and nine months ended September 30, 2024. Third Quarter 2024 Highlights (Year over Year Performance): Total ARR was $9.3 million, up 10% year over yearTotal revenues were $4.2 million, up 4% year over yearGross Prof...
iCAD's ProFound Detection Version 4.0 Gains FDA Clearance
iCAD's ProFound Detection Version 4.0 Gains FDA Clearance Provides 22% Overall Improvement in Detecting Challenging and Aggressive Cancer Subtypes and Enables Clinicians to Incorporate a Prior Exam into Current Screening Analysis NASHUA, N.H., Nov. 12, 2024 (GLOBE NEWSWIRE) -- . (NASDAQ: ICAD) (“iCAD” or the “Company”) a global leader in clinically proven AI-powered cancer detection solutions, announced today that its ProFound Detection Version 4.0 for Digital Breast Tomosynthesis (DBT) has received clearance from the U.S. Food and Drug Administration (FDA). This next-generation AI solu...
iCAD to Attend 15th Annual Craig-Hallum Alpha Select Conference
iCAD to Attend 15th Annual Craig-Hallum Alpha Select Conference NASHUA, N.H., Nov. 06, 2024 (GLOBE NEWSWIRE) -- iCAD, Inc. (NASDAQ: ICAD) (“iCAD” or the “Company”) a global leader on a mission to create a world where cancer can’t hide by providing clinically proven AI-powered breast health solutions, today announced that Dana Brown, Chief Executive Officer, and Eric Lonnqvist, Chief Financial Officer, will attend the 15th Annual Craig-Hallum Alpha Select Conference on Tuesday, November 19, 2024 at the Sheraton New York Times Square Hotel in New York City, New York. Management will be avai...
iCAD to Report Third Quarter 2024 Financial Results on November 13, 20...
iCAD to Report Third Quarter 2024 Financial Results on November 13, 2024 NASHUA, N.H., Nov. 05, 2024 (GLOBE NEWSWIRE) -- . (NASDAQ: ICAD), a global leader in clinically proven AI-powered cancer detection solutions, announced today it will release financial results for the third quarter ended September 30, 2024, after market close and host a conference call at 4:30 PM Eastern Time on Wednesday, November 13, 2024. Earnings call details are as follows: Toll Free: 877-545-0320International: 973-528-0002Participant Access Code: 509249Webcast: About iCAD, Inc.iCAD, Inc. (NASDAQ: ICAD) is a...
iCAD Highlights Global Availability of ProFound Cloud and Internationa...
iCAD Highlights Global Availability of ProFound Cloud and International Expansion Milestones at JFR 2024 NASHUA, N.H. and PARIS, Oct. 03, 2024 (GLOBE NEWSWIRE) -- iCAD, Inc. (NASDAQ: ICAD) (“iCAD” or the “Company”) a global leader in clinically proven AI-powered cancer detection solutions, today announced its participation in the 72nd edition of the Journées Francophones de Radiologie (JFR) 2024 Meeting, taking place from October 4-7 in Paris, France. At JFR, iCAD will premier ProFound Cloud, a secure, scalable SaaS platform designed to deliver the company’s advanced AI solutions to healt...
iCAD to Participate in the iAccess Alpha Buyside Best Ideas Fall Confe...
iCAD to Participate in the iAccess Alpha Buyside Best Ideas Fall Conference 2024 NASHUA, N.H., Sept. 11, 2024 (GLOBE NEWSWIRE) -- iCAD, Inc. (NASDAQ: ICAD) (“iCAD” or the “Company”) a global leader on a mission to create a world where cancer can’t hide by providing clinically proven AI-powered breast health solutions, announced today that management is participating in the iAccess Alpha Buyside Best Ideas Fall Conference 2024 on September 24 and 25, 2024. CEO, Dana Brown and CFO, Eric Lonnqvist will deliver a company presentation at 11:00 am ET on September 24, and host one-on-one meeting...
iCAD Reports Financial Results for Second Quarter Ended June 30, 2024
iCAD Reports Financial Results for Second Quarter Ended June 30, 2024 NASHUA, N.H., Aug. 13, 2024 (GLOBE NEWSWIRE) -- iCAD, Inc. (NASDAQ: ICAD) (“iCAD” or the “Company”) a global leader on a mission to create a world where cancer can’t hide by providing clinically proven AI-powered breast health solutions, today reported its financial and operating results for the three and six months ended June 30, 2024. Second Quarter 2024 Highlights (Year over Year Performance): Total ARR was $9.2 million, up 7%Total revenues were $5.0 million, up 21%Gross Profit Margin was 84%, up from 81%GAAP Net...
iCAD to Report Second Quarter 2024 Financial Results on August 13, 202...
iCAD to Report Second Quarter 2024 Financial Results on August 13, 2024 NASHUA, N.H., Aug. 06, 2024 (GLOBE NEWSWIRE) -- . (NASDAQ: ICAD), a global leader in clinically proven AI-powered cancer detection solutions, announced today it will release financial results for the second quarter ended June 30, 2024 after market close and host a conference call at 4:30 PM Eastern Time on Tuesday, August 13, 2024. Earnings call details are as follows: Toll Free: 888-506-0062International: 973-528-0011Participant Access Code: 227167Webcast: About iCAD, Inc.iCAD, Inc. (NASDAQ: ICAD) is a global lead...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.